BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10517497)

  • 41. Comparative heat sensitivity of murine and human hemopoietic progenitors and clonogenic leukemia cells.
    Gidáli J; Fehér I; Kovács P
    Stem Cells; 1994 Sep; 12(5):533-8. PubMed ID: 7804126
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Guanine arabinoside as a bone marrow-purging agent.
    Kurtzberg J
    Ann N Y Acad Sci; 1993 Jun; 685():225-36. PubMed ID: 8363226
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The cytotoxicity of alkyl-lysophospholipid on clonogenic leukemia cells and on normal bone marrow progenitor cells is highly, but differentially, increased by cryopreservation.
    Verdonck LF; Heesbeen EC; van Heugten HG; Staal GE; Rijksen G
    Bone Marrow Transplant; 1992 Apr; 9(4):241-5. PubMed ID: 1600412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
    Maki G; Tam YK; Berkahn L; Klingemann HG
    Bone Marrow Transplant; 2003 Jun; 31(12):1119-25. PubMed ID: 12796791
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Purging of small cell lung cancer cells from human bone marrow using ethiofos (WR-2721) and light-activated merocyanine 540 phototreatment.
    Meagher RC; Rothman SA; Paul P; Koberna P; Willmer C; Baucco PA
    Cancer Res; 1989 Jul; 49(13):3637-41. PubMed ID: 2543500
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol).
    Capizzi RL
    Eur J Cancer; 1996; 32A Suppl 4():S5-16. PubMed ID: 8976816
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus.
    Rahman MM; Madlambayan GJ; Cogle CR; McFadden G
    Cytokine Growth Factor Rev; 2010; 21(2-3):169-75. PubMed ID: 20211576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Granulocyte colony-stimulating factor and amifostine (Ethyol) synergize to enhance hemopoietic reconstitution and increase survival in irradiated animals.
    Patchen ML; MacVittie TJ
    Semin Oncol; 1994 Oct; 21(5 Suppl 11):26-32. PubMed ID: 7526469
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Purging leukemic cells from simulated human remission marrow with alkyl-lysophospholipid.
    Okamoto S; Olson AC; Vogler WR; Winton EF
    Blood; 1987 May; 69(5):1381-7. PubMed ID: 3471282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging.
    Gautam SC; Xu YX; Dumaguin M; Janakiraman N; Chapman RA
    Bone Marrow Transplant; 2000 Mar; 25(6):639-45. PubMed ID: 10734298
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems.
    Roots-Weiss A; Papadimitriou C; Serve H; Hoppe B; Koenigsmann M; Reufi B; Oberberg D; Thiel E; Berdel WE
    Bone Marrow Transplant; 1997 Jun; 19(12):1239-46. PubMed ID: 9208119
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of mafosfamide on the clonogenic cells in precursor B acute lymphoblastic leukemia: significance for ex vivo purging of bone marrow.
    Kramer B; Makrynikola V; Bradstock K
    Prog Clin Biol Res; 1992; 377():41-7. PubMed ID: 1438438
    [No Abstract]   [Full Text] [Related]  

  • 55. Potential of phenylalanine methylester as a bone marrow purging agent.
    Rosenfeld CS
    Blood; 1992 Nov; 80(9):2401-5. PubMed ID: 1384802
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging.
    Bergan R; Hakim F; Schwartz GN; Kyle E; Cepada R; Szabo JM; Fowler D; Gress R; Neckers L
    Blood; 1996 Jul; 88(2):731-41. PubMed ID: 8695822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors.
    Cazzola M; Bergamaschi G; Dezza L; D'Uva R; Ponchio L; Rosti V; Ascari E
    Cancer Res; 1991 Jan; 51(2):536-41. PubMed ID: 1985771
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Purging of acute myeloid leukaemia cells from stem cell grafts by hyperthermia: enhancement of the therapeutic index by the tetrapeptide AcSDKP and the alkyl-lysophospholipid ET-18-OCH(3).
    Wierenga PK; Setroikromo R; Vellenga E; Kampinga HH
    Br J Haematol; 2000 Dec; 111(4):1145-52. PubMed ID: 11167754
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Purging of contaminating breast cancer cells from hematopoietic stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation.
    Marini FC; Snell V; Yu Q; Zhang X; Singletary SE; Champlin R; Andreeff M
    Clin Cancer Res; 1999 Jun; 5(6):1557-68. PubMed ID: 10389945
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Purging of tumor cells from leukapheresis products: experimental and clinical aspects.
    Kvalheim G; Wang MY; Pharo A; Holte H; Jacobsen E; Beiske K; Kvaløy S; Smeland E; Funderud S; Fodstad O
    J Hematother; 1996 Aug; 5(4):427-36. PubMed ID: 8877718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.